Evidence map›Paper›PMID 40253563›Full record

Trial reportHepatology international2025

Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study.

Huili Guo, Lili Wu, Chengyou Yu, Huiying Yu, Wenjian Deng, Qiyi Zhao, Zhishuo Mo, Bingliang Lin, Zhiliang Gao, Xiaoyan Li

Abstract readClinical Trial, Phase IV
PubMed Publisher
In one paragraph

Trial report in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Huili Guo *Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.ORCID http://orcid.org/0000-0003-2315-0717
Lili Wu *Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Chengyou Yu *Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Huiying YuDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Wenjian DengChaozhou Central Hospital, Chaozhou, 521000, Guangdong, China.
Qiyi ZhaoDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Zhishuo MoDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Bingliang LinDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China.
Zhiliang GaoDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China. gaozhl@mail.sysu.edu.cn.
Xiaoyan LiDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, No 600 Tianhe Road, Guangzhou, 510630, Guangdong Province, China. lixy387@mail.sysu.edu.cn.

Funding

Science and Technology Planning Project Fundamental and Applied Fundamental Research Topics of Guangzhou 2023A04J1091
6 · The paper itself

Abstract

backgroundSoluble PD-1 (sPD-1) has emerged as a potential biomarker in chronic hepatitis B (CHB), but its predictive value for treatment response remains unclear.

objectiveTo examine the relationship between sPD-1 dynamics and HBsAg loss in HBeAg-negative CHB patients undergoing IFN-based therapy and assess the potential of sPD-1 as a biomarker for treatment response.

methodsWe enrolled 222 HBeAg-negative CHB patients from a prospective study. Patients received at least 48 weeks of PEG-IFNα-2b therapy and were grouped based on HBsAg status at week 48 (loss vs. persistence). Peripheral blood sPD-1 levels were measured by ELISA, and PD-1 expression on CD4

resultsAmong the patients, 38.7% (86/222) achieved HBsAg loss. After PSM, both the HBsAg loss and HBsAg persistence groups included 74 patients, respectively. A reduction in HBsAg of more than 70% at week 12 (p = 0.012) and baseline sPD-1 level lower than 100 pg/mL (p = 0.016) were identified as independent predictors of HBsAg loss. sPD-1 levels showed a positive correlation with HBsAg levels, whereas PD-1 expression on peripheral CD4

conclusionssPD-1 may serve as a potential biomarker for predicting HBsAg loss in HBeAg-negative CHB patients undergoing IFN-based therapy.

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B Surface AntigensInterferon alpha-2Programmed Cell Death 1 ReceptorAdolescentAdultAgedBiomarkersFemaleHepatitis B e AntigensHumansInterferon-alphaMaleMiddle AgedPolyethylene GlycolsAntiviral AgentsBiomarkersHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaInterferon alpha-2PDCD1 protein, humanpeginterferon alfa-2bPolyethylene GlycolsProgrammed Cell Death 1 ReceptorRecombinant ProteinsBiomarkerChronic hepatitis BHBsAg lossIFNα therapySoluble PD-1

Identifiers

PMID40253563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.